Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review

Bhagat Singh; Dheer Singh; Vinod Verma; Ramakant Yadav; Raj Kumar

doi:10.1016/j.jpha.2021.12.003

Volume 12 Issue 2

May 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2022 > 12(2): 215-220

Bhagat Singh, Dheer Singh, Vinod Verma, Ramakant Yadav, Raj Kumar. Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review[J]. Journal of Pharmaceutical Analysis, 2022, 12(2): 215-220. doi: 10.1016/j.jpha.2021.12.003

Citation:

Bhagat Singh, Dheer Singh, Vinod Verma, Ramakant Yadav, Raj Kumar. Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review[J]. Journal of Pharmaceutical Analysis, 2022, 12(2): 215-220. doi: 10.1016/j.jpha.2021.12.003

Citation:

PDF( 871 KB)

Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review

doi: 10.1016/j.jpha.2021.12.003

a. Department of Medical Laboratory Technology, Faculty of Paramedical Sciences, Uttar Pradesh University of Medical Sciences, Etawah, 206130, India;
b. Department of Anaesthesiology and Critical Care, Uttar Pradesh University of Medical Sciences, Etawah, 206130, India;
c. Stem Cell Research Centre, Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India;
d. Department of Neurology, Uttar Pradesh University of Medical Sciences, Etawah, 206130, India;
e. Department of Neurosurgery, Uttar Pradesh University of Medical Sciences, Etawah, 206130, India

Received Date: Mar. 12, 2021
Accepted Date: Dec. 14, 2021
Rev Recd Date: Dec. 04, 2021
Publish Date: Dec. 17, 2021

Abstract

Abstract

As of August 16, 2021, there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease (COVID-19), and the pandemic remains a global challenge. To date, no effective and approved drugs are available for the treatment of COVID-19. Angiotensin-converting enzyme 2 (ACE2) plays a crucial role in the invasion into host cells by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19. Notably, ACE2 density is influenced by medical conditions, such as hypertension, or by drugs, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which can change the fate of SARS-CoV-2 infectivity. ACE2 is a target for these drugs and can be manipulated to limit the viral entry and replication within the cells. Different strategies aimed at blocking ACE2 with small molecules, peptides, and antibodies, or by neutralizing the virus through its competitive binding with human recombinant soluble ACE2 (hrsACE2) are currently under investigation. In this article, we review the current state of knowledge that emphasizes the need to find effective therapeutic agents against COVID-19 by exploiting ACE2 as a potential target. The increased soluble ACE2 levels and the application of hrsACE2 in patients with COVID-19 can be implemented to control the disease. It has not yet been established whether hypertension and other comorbidities, independent of age, have a direct role in COVID-19. Therefore, the use of renin-angiotensin system inhibitors, ACEIs and ARBs, should not be discontinued during COVID-19 treatment.
- COVID-19,
- ACE2 receptors,
- hrsACE2,
- ACE inhibitors,
- RAS,
- AT₁R blocker

FullText(HTML)

References(70)

References

P. Zhou, X-L. Yang, X.-G. Wang, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579 (2020) 270-273

E. Cure, M.C. Cure, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic, Diabetes Metab. Syndr. 14 (2020) 349-350

W. Li, M.J. Moore, N. Vasilieva, et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 426 (2003) 450-454

M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181(2020) 271-280.e1-e8

L. Fang, G. Karakiulakis, M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 8 (2020), e21

J. Watkins, Preventing a COVID-19 pandemic, BMJ 368 (2020), m810

M. Esler, D. Esler, Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J. Hypertens. 38 (2020) 781-782

J. H. Diaz, Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19, J. Travel Med. 27 (2020), taaa041

W. Li, C. Zhang, J. Sui, et al., Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2, EMBO J. 24 (2005) 1634-1643

W. Ni, X. Yang, D. Yang, et al., Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19, Crit. Care. 24 (2020), 422

I. Hamming, W. Timens, M.L.C. Bulthuis, et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol. 203 (2004) 631-637

A.H. J. Danser, M. Epstein, D. Batle, Renin-Angiotensin System Blockers and the COVID-19: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers, Hypertension, 75 (2020) 1382-1385

R.A.S. Santos, W.O. Sampaio, A.C. Alzamora, et al., The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin (1-7), Physiol. Rev. 98 (2018) 505-553

S. Keidar, M. Kaplan, A. Gamliel-Lazarovich, ACE2 of the heart: from angiotensin I to angiotensin (1-7), Cardiovasc. Res. 73 (2007) 463-469

H.E. Yim, K.H. Yoo, Renin-angiotensin system - considerations for hypertension and kidney, 6, Electrol. Blood Pres., 2008, pp. 42–50

S.R. Tipnis, N.M. Hooper, R. Hyde, et al., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase, J. Biol. Chem. 275 (2000) 33238-33243

S. Patel, A. Rauf, H. Khan, et al., Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies, Biomed. Pharmacother, 94 (2017) 317-325

C. Liu, Q. Zhou, Y. Li, et al., Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases, ACS Cent. Sci. 6 (2020) 315-331

M. Ye, J. Wysocki, J. William, et al, Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes, J. Am. Soc. Nephrol. 17 (2006) 3067-3075

M. Horiuchi, M. Akishita, V.J. Dzau, Recent progress in angiotensin II type 2 receptor research in the cardiovascular system, Hypertension 33 (1999) 613-621

T. Kawai, T. Takayanagi, S.J. Forrester, et al., Vascularadam17 (a disintegrin and metalloproteinase domain 17) is required for angiotensin ii/beta-aminopropionitrile-induced abdominal aortic aneurysm, Hypertension. 70 (2017) 959-963

T. Takayanagi, S.J. Forrester, T. Kawai, et al., Vascularadam17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin ii, Hypertension 68 (2016) 949-955

K. Kuba, Y. Imai, S. Rao, et al., A crucial role of angiotensin-converting enzyme 2 (ace2) in sars coronavirus induced lung injury, Nat. Med. 11 (2005) 875-879

X. Zou, K. Chen, J. Zou, et al., The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection, Front. Med. 14 (2020) 185-192

D. Wrapp, N. Wang, K.S. Corbett, et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science 367 (2020) 1260-1263

F. Zhou, T. Yu, R. Du, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet 395 (2020) 1054-1062

K. Kuba, Y. Imai, T. Ohto-Nakanishi, et al., Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters, Pharmacol. Ther. 128 (2010) 119-128

F. Li, W. Li, M. Farzan, et al., Structure of SARS coronavirus spike receptor-binding domain complexed with a receptor, Science 309 (2005) 1864-1868

H.P. Jia, D.C. Look, P. Tan, et al., Ectodomain shedding of angiotensin-converting enzyme 2 in human airway epithelia, Am. J. Physiol. Lung Cell. Mol. Physiol. 297 (2009) L84-L96

A. Heurich, H. Hofmann-Winkler, S. Gierer, et al., TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein, J. Virol. 88 (2014) 1293-1307

F. Li, Structure, function, and evolution of coronavirus spike proteins, Annu. Rev. Virol. 3 (2016) 237-261

Y.T.-C. Yu, S.-C. Chien, I.-Y. Chen, et al., Surface vimentin is critical for the cell entry of SARS-CoV, J. Biomed. Sci. 23 (2016), 14

Y. Inoue, N. Tanaka, Y. Tanaka, et al., Clathrin dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted, J. Virol. 81 (2007) 8722-8729

J. Wysocki, A. Goodling, M. Burgaya, et al., Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease, Am. J. Physiol. Renal. Physiol. 313 (2017) F487-F494

L. Bitker, L.M. Burrell, Classic and non-classic renin-angiotensin systems in the critically ill, Crit. Care Clin. 35 (2019) 213-227

M. Alimian, A. Pournajafian, A. Kholdebarin, et al., Analgesic effects of paracetamol and morphine after elective laparotomy surgeries, Anesth. Pain Med. 4 (2014), e12912

D. Gurwitz, Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics, Drug Dev. Res. 81 (2020) 537-540

C.M. Ferrario, J. Jessup, M.C. Chappell, et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation 111 (2005) 2605-2610

E.M. Mortensen, B. Nakashima, J. Cornell, et al., Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes, Clin. Infect. Dis. 55 (2012) 1466-1473

M.R. Deshotels, H. Xia, S. Sriramula, et al., Angiotensin II mediates angiotensin-converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism, Hypertension 64 (2014) 1368-1375

Y. Imai, K. Kuba, S. Rao, et al., Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature 436 (2005) 112-116

Y.-M. Yan, X. Shen, Y.-K. Cao, et al., Discovery of anti-2019-nCoV agents from Chinese patent drugs toward respiratory diseases via docking screening, Preprints. https://www.preprints.org/manuscript/202002.0254/v1.

C. Börner, V. Höllt, J. Kraus. Mechanisms of the inhibition of nuclear factor kappab by morphine in neuronal cells, Mol. Pharmacol. 81 (2012) 587-597

H. Zhang, A. Baker. Recombinant human ace2: acing out angiotensin ii in ards therapy, Crit. Care 21 (2017), 305

J. Guo, Z. Huang, L. Lin, et al., Coronavirus disease 2019 (covid-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, J. Am. Heart Assoc. 9 (2020), e016219

K.M.M. Colafella, E. Uijl, J. Danser, Interference with the Renin-Angiotensin Aystem (RAS): Classical Inhibitors and Novel Approaches, in: Encyclopedia of Endocrine Diseases, 2nd Edition, Vol. 3, Elsevier, 2018, pp XXX-XXX

M. Haschke, M. Schuster, M. Poglitsch, et al., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects, Clin. Pharmacokinet. 52 (2013) 783-792

A. Khan, C. Benthin, B. Zeno, et al., A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome, Crit. Care 21 (2017), 234

S. Krishnamurthy, R.F. Luckey, N. Kolliputi, Soluble ACE2 as a potential therapy for COVID-19, Am. J. Physiol. Cell Physiol. 320 (2021) C279-C281

H. Gu, Z. Xie, T. Li, et al., Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus, Sci. Rep. 6 (2016), 19840

Z. Zou, Y. Yan, Y. Shu, et al., Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections, Nat. Commun. 5 (2014), 3594

S. Shi, M. Qin, B. Shen, et al., Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol. 5 (2020) 802-810

G.Y. Oudit, Z. Kassiri, C. Jiang, et al., SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS, Eur. J. Clin. Invest. 39 (2009) 618-625

R. Basu, M. Poglitsch, H. Yogasundaram, et al., Roles of angiotensin peptides and recombinant human ACE2 in heart failure, J. Am. Coll. Cardiol. 69 (2017) 805-819

X. Zhang, S. Li, S. Niu, ACE2 and COVID-19 and the resulting ARDS, Postgrad. Med. J. 96 (2020) 403-407

Y. Liu, Y. Yang, C. Zhang, et al., Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci. China Life Sci. 63 (2020) 364-374

T.T. Choksi, H. Zhang, T. Chen, et al., Outcomes of Hospitalized COVID-19 Patients Receiving Renin-Angiotensin System Blockers and Calcium Channel Blockers. Am. J. Nephrol. 52 (2021) 250-260

R. Dijkman, M.F. Jebbink, M. Deijs, et al., Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63, J. Gen. Virol. 93 (2012) 1924-1929

B. Singh, C. Ram, R. Singh, Angiotensin-1 converting enzyme (ACE) inhibitory activity of peptides isolated from bovine milk fermented with Lactobacillus helveticus NCDC 288, Milchwissenschaft. 66 (2011) 429-432

B. Singh, C. Ram, D. Singh, et al., Potential of Novel Bioactive Peptides as Functional Food Ingredients in Preventing Cardiovascular Disease, in: Alternative and Replacement Foods, Vol. 17, Elsevier, 2018, pp. 411-431

C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020) 497-506

L.G. Gilstrap, G.C. Fonarow, A.S. Desai, et al., Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized with Heart Failure with Reduced Ejection Fraction, J. Am. Heart Assoc. 6 (2017), e004675

K. Matsushita, N. Ding, M. Kou, et al., The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis, Glob. Heart 15 (2020), 64

C. Savoia, M. Volpe, R. Kreutz, Hypertension, a Moving Target in COVID-19: Current Views and Perspectives, Circ. Res. 128 (2021) 1062-1079

S. Singh, A.K. Offringa-Hup, S.J.J. Logtenberg, et al., Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients with Severe Acute Respiratory- Coronavirus 2, Hypertension 78 (2021) 165-173

B. Singh, D. Singh, K. Pant, et al., A Review on Current Status of SARS-CoV-2 (2019-nCoV): Its Diagnosis and Challenges, in: Highlights on Medicine and Medical Science, Vol.14, Book Publisher International, India, 2021, pp. 142-158

C. Lei, K. Qian, T. Li, et al., Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig, Nat. Commun. 11 (2020), 2070

X. Tian, C. Li, A. Huang, et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect. 9 (2020) 382-385

A.-W. Struck, M. Axmann, S. Pfefferle, et al, hexapeptide of the receptor-binding domain of SARS coronavirus spike protein blocks viral entry into host cells via the human receptor ACE2, Antiviral Res. 94 (2012) 288-296

J. Cohen, Vaccine designers take first shots at COVID-19, Science 368 (2020) 14-16

Relative Articles

Supplements(0)

Cited By

Proportional views